Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of itaconic acid in preparation of medicine for treating or relieving allergic airway inflammation diseases

A technology of airway inflammation and itaconic acid, applied in the direction of allergic diseases, drug combinations, respiratory diseases, etc., to achieve significant effects and broaden the effect of drug types

Pending Publication Date: 2021-08-06
THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no research report on the use of itaconic acid in the preparation of medicines for treating or alleviating allergic airway inflammatory diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of itaconic acid in preparation of medicine for treating or relieving allergic airway inflammation diseases
  • Application of itaconic acid in preparation of medicine for treating or relieving allergic airway inflammation diseases
  • Application of itaconic acid in preparation of medicine for treating or relieving allergic airway inflammation diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: In vivo experiments verify that itaconic acid intervention effectively inhibits OVA-induced allergic airway inflammation;

[0032] (1) Experimental animals:

[0033] Eighteen SPF (specific pathogen free) female C57BL / J mice aged 5 to 6 weeks (14 to 16 g) were purchased from the Experimental Animal Center of Anhui Province, and randomly divided into control group (Vehicle group) and model group (OVA group) and itaconic acid intervention group (OVA+ITA group). Experiments were repeated three times.

[0034] (2) Allergic airway inflammation model:

[0035] After 3 days of adaptation, the model group and the itaconic acid intervention group were injected intraperitoneally with 0.5ml ovalbumin (Ovalbumin, OVA) suspension (containing 1mg aluminum potassium sulfate and 10ug ovalbumin) on the 0th day and the 7th day, and the control group Inject an equal volume of normal saline solution (containing 1mg aluminum potassium sulfate). From the 14th day, the model gro...

Embodiment 2

[0048] Embodiment 2: in vitro experiment

[0049] (1) The mouse macrophage cell line Raw264.7 was purchased from the Cell Bank of the Chinese Academy of Sciences, and the cells were planted in a 96-well culture plate at a density of 2.5×10^4 / well, and were divided into three groups, the control group, Staphylococcus aureus stimulated group, itaconic acid intervention group. Raw264.7 cells were stimulated with Staphylococcus aureus (S.aureus, strain NCTC8325), and the intervention group was treated with itaconic acid (100uM).

[0050] (2) Mitochondrial ROS and mitochondrial membrane potential detection, MitoSox Red (5 μM) staining was used to detect mitochondrial ROS in Raw264.7 cells, and MitoTracker Red CMXRos (1 μM) staining was used to detect mitochondrial membrane potential.

[0051] (3) XFe96 cell energy metabolism analyzer (Agilent, Seahorse Bioscience) was used to determine the effect of itaconic acid on mitochondrial respiratory function in Raw264.7 cells stimulated b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of airway inflammation medicine application, and relates to application of itaconic acid in preparation of a medicine for treating or relieving allergic airway inflammation diseases. In the application, itaconic acid inhibits lung tissue inflammatory cell infiltration, mucus secretion, Th2 cytokine generation, NLRP3 inflammasome activation and oxidative stress injury in a targeted mode for treating or relieving allergic airway inflammation. According to the application, the immune metabolite itaconic acid is introduced into the treatment of the allergic airway inflammation disease for the first time, a new method for treating or relieving the allergic airway inflammation is found, and a new target and a brand new idea are provided for preparing the medicine for treating the allergic airway inflammation disease. The itaconic acid is an endogenous immune metabolite and has the characteristics of high safety and low toxicity, and the application of the itaconic acid to the development process of drugs related to the allergic airway inflammation diseases broadens the types of drugs for treating the allergic airway inflammation diseases such as asthma, allergic bronchitis and allergic rhinitis.

Description

technical field [0001] The invention relates to the medical application field of airway inflammation, and relates to a new application of a substance, in particular to an application of itaconic acid in the preparation of a medicine for treating or alleviating allergic airway inflammation. Background technique [0002] Itaconic acid is an important chemical raw material, also known as methylene succinic acid, methylene succinic acid, formosuccinic acid, etc. Itaconic acid and toluidine undergo a series of reaction processes to produce 4-[1-methylbenzene-2-pyrrolidone-4-yl]-methoxybenzoic acid, which is esterified with coenzyme A in the body , has a strong inhibitory effect on cholesterol synthase and fatty acid synthase. Thereby inhibiting the synthesis of fatty acids and cholesterol in the human body, it is a new drug for preventing and treating various diseases such as arteriosclerosis, diabetes and obesity. [0003] During in vivo metabolism, the immune metabolite Itaco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/194A61K45/00A61P37/08A61P11/00A61P11/06A61P11/02
CPCA61K31/194A61K45/00A61P37/08A61P11/00A61P11/06A61P11/02
Inventor 吴惠梅谢邱梦赵翠翠章海云
Owner THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com